Home / Directory / Ketamine in OCD: Efficacy and Effects on Stress and Cognitio
Recruiting trial

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

Vienna, Austria · Recruiting (ClinicalTrials.gov)

Observational/other study registered on ClinicalTrials.gov. Condition: Obsessive-Compulsive Disorder, Psychiatric Disorder. Interventions listed: Ketamine 50 MG/ML Blinded; Midazolam; Ketamine 50 MG/ML Open Label. Lead sponsor: Medical University of Vienna. Sites in: Austria (1 site).

Trial listings come from public registries. Taking part is up to the study team, who will check your eligibility. Recruitment status can change at any time, so check the registry record first.

Type
Recruiting trial
Location
Vienna, Austria
Status
Recruiting (ClinicalTrials.gov)
Registry
ClinicalTrials.gov · NCT05577585
Sponsor
Medical University of Vienna
Condition
Obsessive-Compulsive Disorder, Psychiatric Disorder
Website
https://clinicaltrials.gov/study/NCT05577585
Source
https://clinicaltrials.gov/study/NCT05577585
Last verified
21 October 2026

About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.

Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.

Follow access news each week

New trials, approvals and access routes, UK and Europe first.

Subscribe free →